Emerging Options for Patients with Atrial Fibrillation - European Medical Journal
×

Browse

Emerging Options for Patients with Atrial Fibrillation

| Download as | PDF
Chairpeople:
Jeffrey Weitz,1 John Camm2
Speakers:
Christian Ruff,3 Andreas Goette,4 Jack Ansell5
Disclosure:

Dr Jeffrey Weitz and Prof John Camm have received fees for consultancy and advisory boards from Daiichi Sankyo, Bristol-Meyers Squibb, Pfizer, Bayer, Janssen, and Boehringer Ingelheim. Dr Jeffrey Weitz and Prof John Camm have also received fees for consultancy and advisory board from Portola and Boston Scientific, respectively. Dr Christian Ruff has received fees for consultancy and advisory boards from Boehringer Ingelheim, Daiichi Sankyo, Bristol-Meyers Squibb, Alere, Beckman Coulter, and research support from Daiichi Sankyo, AstraZeneca, Bristol-Meyers Squibb, Sanofi-Aventis, Merck, Eisai, and Intarcia. Prof Andreas Goette has received honoraria from Daiichi Sankyo, whilst Dr Jack Ansell has received fees for consultancy from Daiichi Sankyo, BMS, Pfizer, Janssen, Boehringer Ingelheim, and Perosphere.

Acknowledgements:

Writing assistance was provided by Dr Juliet Bell, associated with apothecom scopemedical, Ltd.

Support:

Medical writing assistance was funded by Daiichi Sankyo. The views and opinions expressed are those of the authors, as expressed during the symposium, and not necessarily of Daiichi Sankyo.

Citation
EMJ Cardiol. ;2:31-37.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Dr Jeffrey Weitz chaired the symposium and welcomed Dr Christian Ruff, who discussed and summarised recent results from key trials of new oral anticoagulants (NOACs) in atrial fibrillation (AF) with a focus on edoxaban. Prof Andreas Goette then evaluated the current guidelines for the use of cardioversion in AF treatment and recent findings from NOAC trials. Dr Jack Ansell described the current management strategies for NOACs and the limitations therein, as well as novel reversal strategies for NOACs currently under development. Finally Prof John Camm, co-chair, summed up the use of NOACs as an alternative to warfarin in the prevention of stroke in patients with AF, and closed the meeting.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.